COX-2, VEGF and tumour angiogenesis
Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from exi...
Gespeichert in:
| Veröffentlicht in: | The surgeon (Edinburgh) 2009-06, Vol.7 (3), p.174-180 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 180 |
|---|---|
| container_issue | 3 |
| container_start_page | 174 |
| container_title | The surgeon (Edinburgh) |
| container_volume | 7 |
| creator | Toomey, D.P Murphy, J.F Conlon, K.C |
| description | Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target. Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells. While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded. |
| doi_str_mv | 10.1016/S1479-666X(09)80042-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67460270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1479666X09800425</els_id><sourcerecordid>67460270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-a55ba0cc2e22b60e565a90741505a4ff18add0c60c010d18de51332a831b52553</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlZ_glIQRMHVSXYn3b0oUtoqFHrwg95CmkxLdD_qZlfov3f7gYIXTzOHd56XeRg75XDDgcvbZx71kkBKOb2E5CoGiESAe6wtIsAA4wj2Wfsn0mJH3r8DCAwBD1mLJxgDj0Wbnfcn00Bcd98Go2FX57Zb1VlRl826cMWCcvLOH7ODuU49nexmh70OBy_9x2A8GT31H8aBiXhcBRpxpsEYQULMJBBK1An0Io6AOprPeaytBSPBAAfLY0vIw1DoOOQzFIhhh11sucuy-KzJVypz3lCa6pyK2ivZiySIHjRB3AZNWXhf0lwtS5fpcqU4qLUdtbGj1q8rSNTGjloXnO0K6llG9vdqp6MJ3G8D1Lz55ahU3jjKDVlXkqmULdy_FXd_CCZ1uTM6_aAV-ffGbd44VFx5oWALWTMg2RAw_AaAiIY1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67460270</pqid></control><display><type>article</type><title>COX-2, VEGF and tumour angiogenesis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Toomey, D.P ; Murphy, J.F ; Conlon, K.C</creator><creatorcontrib>Toomey, D.P ; Murphy, J.F ; Conlon, K.C</creatorcontrib><description>Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target. Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells. While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.</description><identifier>ISSN: 1479-666X</identifier><identifier>EISSN: 2405-5840</identifier><identifier>DOI: 10.1016/S1479-666X(09)80042-5</identifier><identifier>PMID: 19580182</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>angiogenesis ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; COX-2 ; Cyclooxygenase 2 - physiology ; Dinoprostone - physiology ; Humans ; Neoplasms - drug therapy ; Neoplasms - physiopathology ; Neovascularization, Physiologic - drug effects ; Neovascularization, Physiologic - physiology ; non steroidal anti-inflammatory drug ; Surgery ; Up-Regulation - physiology ; Vascular Endothelial Growth Factor A - physiology ; VEGF</subject><ispartof>The surgeon (Edinburgh), 2009-06, Vol.7 (3), p.174-180</ispartof><rights>Royal College of Surgeons of Edinburgh and Royal College of Surgeons in Ireland</rights><rights>2009 Royal College of Surgeons of Edinburgh and Royal College of Surgeons in Ireland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-a55ba0cc2e22b60e565a90741505a4ff18add0c60c010d18de51332a831b52553</citedby><cites>FETCH-LOGICAL-c418t-a55ba0cc2e22b60e565a90741505a4ff18add0c60c010d18de51332a831b52553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1479666X09800425$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19580182$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toomey, D.P</creatorcontrib><creatorcontrib>Murphy, J.F</creatorcontrib><creatorcontrib>Conlon, K.C</creatorcontrib><title>COX-2, VEGF and tumour angiogenesis</title><title>The surgeon (Edinburgh)</title><addtitle>Surgeon</addtitle><description>Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target. Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells. While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.</description><subject>angiogenesis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>COX-2</subject><subject>Cyclooxygenase 2 - physiology</subject><subject>Dinoprostone - physiology</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - physiopathology</subject><subject>Neovascularization, Physiologic - drug effects</subject><subject>Neovascularization, Physiologic - physiology</subject><subject>non steroidal anti-inflammatory drug</subject><subject>Surgery</subject><subject>Up-Regulation - physiology</subject><subject>Vascular Endothelial Growth Factor A - physiology</subject><subject>VEGF</subject><issn>1479-666X</issn><issn>2405-5840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlZ_glIQRMHVSXYn3b0oUtoqFHrwg95CmkxLdD_qZlfov3f7gYIXTzOHd56XeRg75XDDgcvbZx71kkBKOb2E5CoGiESAe6wtIsAA4wj2Wfsn0mJH3r8DCAwBD1mLJxgDj0Wbnfcn00Bcd98Go2FX57Zb1VlRl826cMWCcvLOH7ODuU49nexmh70OBy_9x2A8GT31H8aBiXhcBRpxpsEYQULMJBBK1An0Io6AOprPeaytBSPBAAfLY0vIw1DoOOQzFIhhh11sucuy-KzJVypz3lCa6pyK2ivZiySIHjRB3AZNWXhf0lwtS5fpcqU4qLUdtbGj1q8rSNTGjloXnO0K6llG9vdqp6MJ3G8D1Lz55ahU3jjKDVlXkqmULdy_FXd_CCZ1uTM6_aAV-ffGbd44VFx5oWALWTMg2RAw_AaAiIY1</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Toomey, D.P</creator><creator>Murphy, J.F</creator><creator>Conlon, K.C</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>COX-2, VEGF and tumour angiogenesis</title><author>Toomey, D.P ; Murphy, J.F ; Conlon, K.C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-a55ba0cc2e22b60e565a90741505a4ff18add0c60c010d18de51332a831b52553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>angiogenesis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>COX-2</topic><topic>Cyclooxygenase 2 - physiology</topic><topic>Dinoprostone - physiology</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - physiopathology</topic><topic>Neovascularization, Physiologic - drug effects</topic><topic>Neovascularization, Physiologic - physiology</topic><topic>non steroidal anti-inflammatory drug</topic><topic>Surgery</topic><topic>Up-Regulation - physiology</topic><topic>Vascular Endothelial Growth Factor A - physiology</topic><topic>VEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toomey, D.P</creatorcontrib><creatorcontrib>Murphy, J.F</creatorcontrib><creatorcontrib>Conlon, K.C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The surgeon (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toomey, D.P</au><au>Murphy, J.F</au><au>Conlon, K.C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COX-2, VEGF and tumour angiogenesis</atitle><jtitle>The surgeon (Edinburgh)</jtitle><addtitle>Surgeon</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>7</volume><issue>3</issue><spage>174</spage><epage>180</epage><pages>174-180</pages><issn>1479-666X</issn><eissn>2405-5840</eissn><abstract>Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer. Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis. Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target. Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells. While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>19580182</pmid><doi>10.1016/S1479-666X(09)80042-5</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-666X |
| ispartof | The surgeon (Edinburgh), 2009-06, Vol.7 (3), p.174-180 |
| issn | 1479-666X 2405-5840 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67460270 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | angiogenesis Anti-Inflammatory Agents, Non-Steroidal - pharmacology COX-2 Cyclooxygenase 2 - physiology Dinoprostone - physiology Humans Neoplasms - drug therapy Neoplasms - physiopathology Neovascularization, Physiologic - drug effects Neovascularization, Physiologic - physiology non steroidal anti-inflammatory drug Surgery Up-Regulation - physiology Vascular Endothelial Growth Factor A - physiology VEGF |
| title | COX-2, VEGF and tumour angiogenesis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T14%3A17%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COX-2,%20VEGF%20and%20tumour%20angiogenesis&rft.jtitle=The%20surgeon%20(Edinburgh)&rft.au=Toomey,%20D.P&rft.date=2009-06-01&rft.volume=7&rft.issue=3&rft.spage=174&rft.epage=180&rft.pages=174-180&rft.issn=1479-666X&rft.eissn=2405-5840&rft_id=info:doi/10.1016/S1479-666X(09)80042-5&rft_dat=%3Cproquest_cross%3E67460270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67460270&rft_id=info:pmid/19580182&rft_els_id=S1479666X09800425&rfr_iscdi=true |